An understanding of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways has greatly changed the way metastatic renal cell carcinoma (RCC) is treated. Based on available phase III randomized trials, anti-VEGF agents such as sunitinib, sorafenib, bevacizumab-based therapy, and mTOR-targeted agents such as temsirolimus and everolimus have been used in the treatment armamentarium for this disease. Now that agents directed against these pathways have largely replaced immunotherapy as the standard of care, new questions have emerged and are the subject of ongoing clinical trials. The development of new targeted therapies including axitinib, pazopanib, cediranib, volociximab, tivozanib (AV-951), BAY 73-4506, and c-met inhibitors such as GSK1363089 and ARQ197 may potentially expand the list of treatment options. Sequential and combination targeted therapies are currently under investigation in advanced disease as are adjuvant and neo-adjuvant approaches around nephrectomy.
Ahmad, T. and Eisen, T. ( 2004) Kinase inhibition with BAY 43-9006 in renal cell carcinoma . Clin Cancer Res10: 6388S-92S.
2.
Altomare, D.A. and Testa, J.R. ( 2005) Perturbations of the AKT signaling pathway in human cancer . Oncogene24: 7455-7464.
3.
Atkins, M.B., Hidalgo, M., Stadler, W.M., Logan, T.F., Dutcher, J.P., Hudes, G.R. et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol22: 909-918.
4.
Banks, R.E., Tirukonda, P., Taylor, C., Hornigold, N., Astuti, D., Cohen, D. et al. (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res66: 2000-2011.
5.
Bhargava, P., Esteves, B., Nosov, D.A., Lipatov, O.N., Lyulko, A.A., Anischenko, A.A. et al. (2009) Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC) . J Clin Oncol27: 5032.
6.
Brauch, H., Weirich, G., Brieger, J., Glavac, D., Rodl, H., Eichinger, M. et al. (2000) VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation . Cancer Res60: 1942-1948.
7.
Bukowski, R.M., Kabbinavar, F.F., Figlin, R.A., Flaherty, K., Srinivas, S., Vaishampayan, U. et al. (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol25: 4536-4541.
8.
Choueiri, T.K., Plantade, A., Elson, P., Negrier, S., Ravaud, A., Oudard, S. et al. (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol26: 127-131.
9.
Christensen, J.G. ( 2007) A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol18(Suppl 10): x3-10.
10.
Clifford, S.C., Prowse, A.H., Affara, N.A., Buys, C.H. and Maher, E.R. ( 1998) Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis . Genes Chromosomes Cancer22: 200-209.
11.
Cohen, H.T. and McGovern, F.J. ( 2005) Renal-cell carcinoma. N Engl J Med353: 2477-2490.
12.
Cooney, M.M., Garcia, J., Brell, J., Dreicer, R., Beatty, K., Mekhail, T. et al. (2007) A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. J Clin Oncol25: 15532.
13.
Coppin, C., Porzsolt, F., Awa, A., Kumpf, J., Coldman, A. and Wilt, T. ( 2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev1: CD001425.
14.
Delahunt, B. and Eble, J.N. ( 1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol10: 537-544.
15.
Eder, J.P., Heath, E., Appleman, L., Shapiro, G., Wang, D., Malburg, L. et al. (2007) Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol25: 3526.
16.
Eisen, T., Joensuu, H., Nathan, P., Harper, P., Wojtukiewicz, M., Nicholson, S. et al. (2009) Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer. J Clin Oncol27: 5033.
17.
Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M. et al. (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med356: 125-134.
18.
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C. et al. (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial . Lancet370: 2103-2111.
19.
Escudier, B., Szczylik, C., Hutson, T.E., Demkow, T., Staehler, M., Rolland, F. et al. (2009a) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol27: 1280-1289.
20.
Escudier, B.J., Bellmunt, J., Negrier, S., Melichar, B., Bracarda, S., Ravaud, A. et al. (2009b) Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol27: 5020.
21.
Feldman, D.R., Kondagunta, G.V., Ronnen, E.A., Fischer, P., Chang, R., Baum, M. et al. (2007) Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol25: 5099.
22.
Figlin, R.A., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Negrier, S. et al. (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) . J Clin Oncol26: 5024.
23.
Foster, K., Prowse, A., van den Berg, A., Fleming, S., Hulsbeek, M.M., Crossey, P.A. et al. (1994) Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma . Hum Mol Genet3: 2169-2173.
24.
Fyfe, G.A., Fisher, R.I., Rosenberg, S.A., Sznol, M., Parkinson, D.R. and Louie, A.C. ( 1996) Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy . J Clin Oncol14: 2410-2411.
25.
Garcia, A., Rosen, L., Cunningham, C.C., Nemunaitis, J., Li, C., Rulewski, N. et al. (2007) Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. J Clin Oncol25: 3525.
26.
Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H. et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet7: 85-90.
27.
Harzstark, A.L., Rosenberg, J.E., Weinberg, V.K., Sun, J., Ryan, C.J., Lin, A.M. et al. (2009) A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J Clin Oncol27: 5104.
28.
Heng, D.Y., Rini, B.I., Garcia, J., Wood, L. and Bukowski, R.M. ( 2007) Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer5: 446-451.
29.
Heng, D.Y., Chi, K.N., Murray, N., Jin, T., Garcia, J.A., Bukowski, R.M. et al. (2009) A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer115: 776-783.
30.
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A. et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med356: 2271-2281.
31.
Hudson, C.C., Liu, M., Chiang, G.G., Otterness, D.M., Loomis, D.C., Kaper, F. et al. (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol22: 7004-7014.
32.
Hutson, T.E., Davis, I.D., Machiels, J.P., de Souza, P.L., Hong, B.F., Rottey, S. et al. (2007) Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol25: 5031.
33.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. et al. (2008) Cancer statistics, 2008. CA Cancer J Clin58: 71-96.
34.
Kay, A., Motzer, R., Figlin, R., Escudier, B., Oudard, S., Porta, C. et al. (2009) Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC) . Genitourinary Cancers Symposium, February 26-28, Orlando.
35.
Kenck, C., Wilhelm, M., Bugert, P., Staehler, G. and Kovacs, G. ( 1996) Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol179: 157-161.
36.
Kondo, K., Yao, M., Yoshida, M., Kishida, T., Shuin, T., Miura, T. et al. (2002) Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer34: 58-68.
37.
Kroog, G.S., Feldman, D.R., Kondagunta, G.V., Ginsberg, M.S., Fischer, P.M., Trinos, M.J. et al. (2009) Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol27: 5037.
38.
McDermott, D.F., Regan, M.M., Clark, J.I., Flaherty, L.E., Weiss, G.R., Logan, T.F. et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol23: 133-141.
39.
Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G. et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res9: 327-337.
40.
Merchan, J.R., Pitot, H.C., Qin, R., Liu, G., Fitch, T.R., Picus, J. et al. (2009) Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients . J Clin Oncol27: 5039.
41.
Motzer, R.J. and Russo, P. ( 2000) Systemic therapy for renal cell carcinoma. J Urol163: 408-417.
42.
Motzer, R.J., Bacik, J., Murphy, B.A., Russo, P. and Mazumdar, M. ( 2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol20: 289-296.
43.
Motzer, R.J., Michaelson, M.D., Redman, B.G., Hudes, G.R., Wilding, G., Figlin, R.A. et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol24: 16-24.
44.
Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O. et al. (2007b) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med356: 115-124.
Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S. et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial . Lancet372: 449-456.
47.
Negrier, S., Perol, D., Ravaud, A., Chevreau, C., Bay, J.O., Delva, R. et al. (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer110: 2468-2477.
48.
Rini, B.I. and Small, E.J. ( 2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol23: 1028-1043.
49.
Rini, B.I., Wilding, G., Hudes, G., Stadler, W.M., Kim, S., Tarazi, J.C. et al. (2007) Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol25: 5032.
50.
Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D., Ou, S. et al. (2008) CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. ASCO Genitourinary Cancers Symposium 2008, February 14-16, San Francisco.
51.
Rini, B.I., Garcia, J., Elson, P., Wood, L., Lane, B., Novick, A. et al. (2009a) Neoadjuvant sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). Genitourinary Cancers Symposium, February 26-28, Orlando.
52.
Rini, B.I., Halabi, S., Rosenberg, J., Stadler, W.M., Vaena, D.A., Atkins, J.N. et al. (2009b) Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J Clin Oncol27: LBA5019.
53.
Rixe, O., Bukowski, R.M., Michaelson, M.D., Wilding, G., Hudes, G.R., Bolte, O. et al. (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol8: 975-984.
54.
Rosenberg, J.E., Motzer, R.J., Michaelson, M.D., Redman, B.G., Hudes, G.R., Bukowski, R.M. et al. (2007) Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival. J Clin Oncol25: 5095.
55.
Shaheen, P.E., Rini, B.I. and Bukowski, R.M. ( 2006) Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer5: 78-81.
56.
Shepard, D.R., Rini, B.I., Garcia, J.A., Hutson, T.E., Elson, P., Gilligan, T. et al. (2008) A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol20S: 5123.
57.
Shuin, T., Kondo, K., Torigoe, S., Kishida, T., Kubota, Y., Hosaka, M. et al. (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res54: 2852-2855.
58.
Sridhar, S.S., Hotte, S.J., Mackenzie, M.J., Kollmannsberger, C.K., Haider, M.A., Pond, G.R. et al. (2007) Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH Phase II Consortium. J Clin Oncol25: 5093.
59.
Srinivasan, R., Linehan, W.M., Vaishampayan, U., Logan, T., Shankar, S.M., Sherman, L.J. et al. (2009) A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol27: 5103.
60.
Sternberg, C.N., Szczylik, C., Lee, E., Salman, P.V., Mardiak, J., Davis, I.D. et al. (2009) A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol27: 5021.
61.
Whorf, R.C., Hainsworth, J.D., Spigel, D.R., Yardley, D.A., Burris, H.A., Waterhouse, D.M. et al. (2008) Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol26: 5010.
62.
Witteles, R.M., Telli, M.L., Fisher, G.A. and Srinivas, S. ( 2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. J Clin Oncol26: 9597.
63.
Yagoda, A., Petrylak, D. and Thompson, S. ( 1993) Cytotoxic chemotherapy for advanced renal cell carcinoma . Urol Clin North Am20: 303-321.
64.
Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L. et al. (2003a) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med349: 427-434.
65.
Yang, J.C., Sherry, R.M., Steinberg, S.M., Topalian, S.L., Schwartzentruber, D.J., Hwu, P. et al. (2003b) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol21: 3127-3132.
66.
Yazji, S., Bukowksi, R.M., Kondagunta, V. and Figlin, R. ( 2007) Final results from phase II study of volociximab, an a5B1 anti-integrin antibody, in refractoryi or relapsed metastatic clear cell renal cell carcinomaI (mCCRCC). J Clin Oncol25: 5094.
